<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414426</url>
  </required_header>
  <id_info>
    <org_study_id>11-0265</org_study_id>
    <secondary_id>NCI-2011-01246</secondary_id>
    <nct_id>NCT01414426</nct_id>
  </id_info>
  <brief_title>Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions</brief_title>
  <official_title>Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well vandetanib works in preventing head and neck&#xD;
      cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of&#xD;
      certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming&#xD;
      in patients with premalignant lesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the effect of ZD6474 (vandetanib) compared to placebo on microvessel density&#xD;
      (MVD) from baseline to 3 months in patients at risk for oral squamous cell carcinoma (OSCC)&#xD;
      with preneoplastic lesions.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Change in MVD over 6 months. II. Change in putative targets of ZD6474: tissues will be&#xD;
      analyzed by immunohistochemistry (IHC) for phosphorylated epidermal growth factor receptor&#xD;
      (pEGFR), EGFR, phosphorylated-vascular endothelial growth factor receptor 2 (pVEGFR2),&#xD;
      VEGFR2.&#xD;
&#xD;
      III. Change in proliferative index as measured by Ki-67 IHC. IV. Safety, tolerability, and&#xD;
      adherence to ZD6474 for 6 months in patients at risk for OSCC.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Compare OSCC incidence in both study arms (ZD6474 and placebo).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive vandetanib orally (PO) once daily (QD) for 6 months. Treatment&#xD;
      continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive placebo PO QD for 6 months. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 9 and 12 months and then&#xD;
      every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>A Wilcoxon ranksum test may be used if the normality assumption is not satisfied. Alternatively, change in MVD may be transformed (e.g. log-transformation) to satisfy the normality assumption. Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Weekly during treatment, up to week 24</time_frame>
    <description>Adverse events rate shows the total number of subjects with an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Adhered to Treatment</measure>
    <time_frame>Over 6 months</time_frame>
    <description>Number of participants who Adhered to Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Oral and Other Cancers</measure>
    <time_frame>At 6, 9, and 12 months and then ever 6 months for 2 years</time_frame>
    <description>Number of patients with new cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic Effect of EGFR and VEGFR2 Inhibition</measure>
    <time_frame>Baseline and 3 and 6 months</time_frame>
    <description>Effect of treatment on EGFR and VEGFR2 inhibition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lip and Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Oral Cavity Verrucous Carcinoma</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I (chemoprevention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vandetanib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (chemoprevention)</arm_group_label>
    <other_name>AZD6474</other_name>
    <other_name>ZD6474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (chemoprevention)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (chemoprevention)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (chemoprevention)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (chemoprevention)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological/cytological confirmation of oral cavity dysplasia and one of three&#xD;
             additional criteria:&#xD;
&#xD;
          -  Prior history of OSCC&#xD;
&#xD;
          -  Loss of heterozygosity (LOH) at 3p or 9p&#xD;
&#xD;
          -  Expression by immunohistochemistry (IHC) of budding uninhibited by benzimidazoles 3&#xD;
             (BUB3)/sex determining region Y (SOX4)&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
          -  Females of child bearing age must have a negative serum pregnancy test within 7 days&#xD;
             of first dose of study drug&#xD;
&#xD;
          -  Patients must not have been taking steroids or are on a stable dose of steroids for at&#xD;
             least 14 days before enrollment&#xD;
&#xD;
          -  Patients must have a Karnofsky Performance Score of 70% or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malignancy within the last 5 years other than squamous cell carcinoma of&#xD;
             the head and neck (SCCHN) and superficial non-melanoma skin cancer; patients with a&#xD;
             history of SCCHN must be free of active carcinoma&#xD;
&#xD;
          -  Currently receiving treatment for any malignancy&#xD;
&#xD;
          -  Serum bilirubin &gt; 1.5x the upper limit of reference range (ULRR)&#xD;
&#xD;
          -  Creatinine clearance =&lt; 30 mL/minute (calculated by Cockcroft-Gault formula)&#xD;
&#xD;
          -  Potassium, &lt; 4.0 mmol/L despite supplementation; or above the Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) grade 1 upper limit&#xD;
&#xD;
          -  Magnesium below the normal range despite supplementation, or above the CTCAE grade 1&#xD;
             upper limit&#xD;
&#xD;
          -  Serum calcium above the CTCAE grade 1 upper limit; in cases where the serum calcium is&#xD;
             below the normal range, 2 options would be available: 1) the calcium adjusted for&#xD;
             albumin is to be obtained and substituted for the measured serum value; exclusion is&#xD;
             to then be based on the adjusted for albumin values falling below the normal limit; 2)&#xD;
             Determine the ionized calcium levels; if these ionized calcium levels are out of&#xD;
             normal range despite supplementation, then the patient must be excluded&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 × ULRR&#xD;
&#xD;
          -  Alkaline phosphatase (ALP) &gt; 2.5 x ULRR&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which&#xD;
             in the Investigator's opinion makes it undesirable for the patient to participate in&#xD;
             the trial or which would jeopardize compliance with the protocol&#xD;
&#xD;
          -  Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena&#xD;
             cava syndrome [SVC], New York Heart Association [NYHA] classification of heart disease&#xD;
             &gt; 2 within 3 months before entry; or presence of cardiac disease that, in the opinion&#xD;
             of the Investigator, increases the risk of ventricular arrhythmia&#xD;
&#xD;
          -  History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy,&#xD;
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is&#xD;
             symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained&#xD;
             ventricular tachycardia; atrial fibrillation, controlled on medication is not excluded&#xD;
&#xD;
          -  QTc prolongation with other medications that required discontinuation of that&#xD;
             medication&#xD;
&#xD;
          -  Congenital long QT syndrome or 1st degree relative with unexplained sudden death under&#xD;
             40 years of age&#xD;
&#xD;
          -  Presence of left bundle branch block (LBBB)&#xD;
&#xD;
          -  QTc with Bazett's correction that is unmeasurable or ≥450 msec on screening&#xD;
             electrocardiogram (ECG); (Note: If a subject has a QTc interval &gt;= 450 msec on&#xD;
             screening ECG, the screen ECG may be repeated twice [at least 24 hours apart]; the&#xD;
             average QTc from the three screening ECGs must be &lt; 450 msec in order for the subject&#xD;
             to be eligible for the study)&#xD;
&#xD;
          -  Any concurrent medication with a known risk of inducing Torsades de Pointes, that in&#xD;
             the investigator's opinion cannot be discontinued&#xD;
&#xD;
          -  Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin,&#xD;
             carbamazepine, phenobarbital and St. John's Wort) of Cytochrome P450 3A4 (CYP3A4)&#xD;
             function&#xD;
&#xD;
          -  Hypertension not controlled by medical therapy (systolic blood pressure greater than&#xD;
             160 mm mercury (Hg) or diastolic blood pressure greater than 100 mm Hg)&#xD;
&#xD;
          -  Currently active diarrhea that may affect the ability of the patient to absorb the&#xD;
             ZD6474 or tolerate diarrhea&#xD;
&#xD;
          -  Women who are currently pregnant or breast-feeding&#xD;
&#xD;
          -  Receipt of any investigational agents within 30 days prior to commencing study&#xD;
             treatment&#xD;
&#xD;
          -  Previous enrollment or randomization of treatment in the present study&#xD;
&#xD;
          -  Major surgery within 4 weeks or incompletely healed surgical incision before starting&#xD;
             study therapy&#xD;
&#xD;
          -  Involvement in the planning and conduct of the study (applies to both Astra Zeneca&#xD;
             staff and staff at the study site)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanguy Seiwert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <results_first_submitted>September 17, 2020</results_first_submitted>
  <results_first_submitted_qc>January 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT01414426/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Chemoprevention)</title>
          <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Chemoprevention)</title>
          <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="10.0"/>
                    <measurement group_id="B2" value="49.0" spread="15.0"/>
                    <measurement group_id="B3" value="54.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation</title>
        <description>A Wilcoxon ranksum test may be used if the normality assumption is not satisfied. Alternatively, change in MVD may be transformed (e.g. log-transformation) to satisfy the normality assumption. Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>The outcome measure microvessel density was not collected on any subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemoprevention)</title>
            <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation</title>
          <description>A Wilcoxon ranksum test may be used if the normality assumption is not satisfied. Alternatively, change in MVD may be transformed (e.g. log-transformation) to satisfy the normality assumption. Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates.</description>
          <population>The outcome measure microvessel density was not collected on any subjects</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse events rate shows the total number of subjects with an AE.</description>
        <time_frame>Weekly during treatment, up to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemoprevention)</title>
            <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse events rate shows the total number of subjects with an AE.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Adhered to Treatment</title>
        <description>Number of participants who Adhered to Treatment</description>
        <time_frame>Over 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemoprevention)</title>
            <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Adhered to Treatment</title>
          <description>Number of participants who Adhered to Treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Oral and Other Cancers</title>
        <description>Number of patients with new cancer</description>
        <time_frame>At 6, 9, and 12 months and then ever 6 months for 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemoprevention)</title>
            <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Oral and Other Cancers</title>
          <description>Number of patients with new cancer</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biologic Effect of EGFR and VEGFR2 Inhibition</title>
        <description>Effect of treatment on EGFR and VEGFR2 inhibition</description>
        <time_frame>Baseline and 3 and 6 months</time_frame>
        <population>Outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemoprevention)</title>
            <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Biologic Effect of EGFR and VEGFR2 Inhibition</title>
          <description>Effect of treatment on EGFR and VEGFR2 inhibition</description>
          <population>Outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days</time_frame>
      <desc>Adverse Events were monitored/assessed without regard to the specific Adverse Event Term</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Chemoprevention)</title>
          <description>Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
vandetanib: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
biopsy: Correlative studies&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexander Pearson</name_or_title>
      <organization>UChicago</organization>
      <phone>855-702-8222</phone>
      <email>apearson5@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

